Skip to main content

Advertisement

SpringerLink
Log in

Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users

  • Published:
Journal of Urban Health Aims and scope Submit manuscript

Abstract

During January–April, 2000, 12 cases of acute hepatitis B were reported in Pierce County, Washington, compared with seven in all of 1999. Seven (58.3%) case patients were injection drug users (IDUs), three of whom were coinfected with hepatitis D virus (HDV) and died of fulminant hepatitis. Vaccination clinics were implemented at the local health department and needle exchange program to control the outbreak. We investigated this outbreak to determine risk factors for hepatitis B virus (HBV) transmission among IDUs. Hepatitis B cases were ascertained through routine surveillance and prevaccination testing at vaccination clinics. We conducted a case-control study comparing IDU case patients with HBV-susceptible IDUs identified at the vaccination clinics. Fifty-eight case patients were identified during January–December, 2000, 20 (34.5%) of whom were coinfected with HDV. Thirty-eight case patients (65.5%) reported current IDU. In the case-control study, the 17 case patients were more likely than the 141 controls to report having more than one sex partner [odds ratio (OR)=4.8, 95% confidence interval (CI)=1.5–15.0], injecting more than four times a day (OR=4.5, 95% CI=1.2–15.6) and sharing drug cookers with more than two people (58.8% vs. 14.0%, OR=14.0, 95% CI=2.4–81.5). Results were similar after controlling for syringe sharing in multivariable analysis. IDUs should be vaccinated against hepatitis B and should be advised against sharing drug injection equipment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention. Hepatitis Surveillance Report 57. Atlanta, GA: CDC; 2000.

    Google Scholar 

  2. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655–661.

    CAS  PubMed  Google Scholar 

  3. Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002;92:385–387.

    Article  PubMed  Google Scholar 

  4. Dhopesh VP, Taylor KR, Burke WM. Survey of hepatitis B and C in addiction treatment unit. Am J Drug Alcohol Abuse. 2000;26:703–707.

    Article  CAS  PubMed  Google Scholar 

  5. Lopez-Zetina J, Kerndt P, Ford W, et al. Prevalence of HIV and hepatitis B and selfreported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994–1996. Addiction. 2001;96:589–595.

    Article  CAS  PubMed  Google Scholar 

  6. Polish LB, Gallagher M, Fields HA, et al. Delta hepatitis: molecular biology and clinical and epidemiological features. Clin Microbiol Rev. 1993;6:211–229.

    CAS  PubMed  Google Scholar 

  7. DesJarlais C, Perlis T, Friedman SR, et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990–1997. Am J Public Health. 2000;90:1112–1116.

    CAS  Google Scholar 

  8. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990–1995. Med J Aust. 1997;167:17–20.

    CAS  PubMed  Google Scholar 

  9. Cook PA, McVeigh J, Syed Q, et al. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction. 2001;96:1787–1797.

    Article  CAS  PubMed  Google Scholar 

  10. McCoy CB, Metsch LR, Chitwood DD, et al. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S25-S29.

    PubMed  Google Scholar 

  11. Thiede H, Romero M, Bordelon K, et al. Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users. J Urban Health. 2001;78:264–278.

    CAS  PubMed  Google Scholar 

  12. Hunter GM, Donoghoe MC, Stimson GV, et al. Changes in the injecting risk behaviour of injecting drug users in London, 1990–1993. AIDS. 1995;9:493–501.

    CAS  PubMed  Google Scholar 

  13. Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health. 2000;77:369–382.

    Article  CAS  PubMed  Google Scholar 

  14. Koester S, Hoffer L. “Indirect sharing”: additional HIV risks associated with drug injection. AIDS Public Policy J. 1994;3:100–105.

    Google Scholar 

  15. Mansson AS, Moestrup T, Nordenfelt E, et al. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis. 2000;32:253–258.

    Article  CAS  PubMed  Google Scholar 

  16. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645–653.

    Article  PubMed  Google Scholar 

  17. Centers for Disease Control and Prevention. Hepatitis B vaccination for injection drug users —Pierce County, Washington, 2000. MMWR Morb Mortal Wkly Rep. 2001;50:388–390, 399.

    Google Scholar 

  18. Nakano T, Shapiro CN, Hadler SC, et al. Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. J Gen Virol. 2001;82:2183–2189.

    CAS  PubMed  Google Scholar 

  19. Nainan OV, Cromeans TL, Margolis HS. Sequence-specific, single-primer amplification and detection of PCR products for identification of hepatitis viruses. J Virol Methods. 1996;61:127–134.

    Article  CAS  PubMed  Google Scholar 

  20. Nainan OV, Stevens PE, Taylor PE, et al. Hepatitis B virus (HBV) antibody resistant mutants among mothers and infants with chronic HBV infection. In: Rizetto, M, Purcell, RH, Gerin, JL, Verme, G, eds. Viral Hepatitis and Liver Disease. Turin, Italy: Edizioni Minerva Medica; 1997:132–134.

    Google Scholar 

  21. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 1984;12:387–395.

    CAS  PubMed  Google Scholar 

  22. Abdala N, Reyes R, Carney JM, et al. Survival of HIV-1 in syringes: effects of temperature during storage. Subst Use Misuse. 2000;35:1369–1383.

    CAS  PubMed  Google Scholar 

  23. Clatts MC, Heimer R, Abdala N, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr. 1999;22:194–199.

    CAS  PubMed  Google Scholar 

  24. Shah SM, Shapshak P, Rivers JE, et al. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:301–306.

    CAS  PubMed  Google Scholar 

  25. Heimer R, Khoshnood K, Jariwala-Freeman B, et al. Hepatitis in used syringes: the limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens. J Infect Dis. 1996;173:997–1000.

    CAS  PubMed  Google Scholar 

  26. Bond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981;1:550–551.

    Article  CAS  PubMed  Google Scholar 

  27. van Bueren J, Simpson RA, Jacobs P, et al. Survival of human immunodeficiency virus in suspension and dried onto surfaces. J Clin Microbiol. 1994;32:571–574.

    PubMed  Google Scholar 

  28. Alter MJ, Hadler SC. Delta hepatitis and infection in North America. Prog Clin Biol Res. 1993;382:243–250.

    CAS  PubMed  Google Scholar 

  29. Vlahov D, Junge B, Brookmeyer R, et al. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:400–406.

    CAS  PubMed  Google Scholar 

  30. Hagan H, DesJarlais DC, Purchase D, et al. An interview study of participants in the Tacoma, Washington, syringe exchange. Addiction. 1993;88:1691–1697.

    Article  CAS  PubMed  Google Scholar 

  31. Hagan H, Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995;85:1531–1537.

    CAS  PubMed  Google Scholar 

  32. Hagan H, McGough JP, Thiede H, et al. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149:203–213.

    CAS  PubMed  Google Scholar 

  33. Hutchinson SJ, Goldberg DJ, Gore SM, et al. Hepatitis B outbreak at Glenochil prison during January to June 1993. Epidemiol Infect. 1998;121:185–191.

    Article  CAS  PubMed  Google Scholar 

  34. Stevenson J, Tannahill M, Biggs V. An outbreak of acute hepatitis B infection among injecting drug users in Inverclyde, Scotland. Commun Dis Public Health. 2001;4:60–63.

    CAS  PubMed  Google Scholar 

  35. Streetly A, Perkins A, Tucker KM, et al. An outbreak of hepatitis B among intravenous drug users in Medway. Community Med. 1988;10:147–155.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unired States Public Health Service, Division of Viral Heparitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mail Stop G-37, 30333, Atlanta, GA

    Stephanie R. Bialek,  William A. Bower,  T. Nakano,  Omana Nainan,  Ian T. Williams &  Beth P. Bell

  2. Tacoma Pierce County Health Department, Tacoma, Washington, DC

    Karen Mottram

  3. Point Defiance AIDS Projects, Tacoma, Washington, DC

    Dave Purchase

Authors
  1. Stephanie R. Bialek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William A. Bower
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karen Mottram
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dave Purchase
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Omana Nainan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ian T. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Beth P. Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanie R. Bialek.

Additional information

None of the authors have any financial arrangements with any company whose product is pertinent to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bialek, S.R., Bower, W.A., Mottram, K. et al. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. J Urban Health 82, 468–478 (2005). https://doi.org/10.1093/jurban/jti094

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1093/jurban/jti094

Keywords

Search

Navigation